Faster Site Start-Up in Rare Disease Trials: Tactics for Accelerated Activation

The Site Activation Challenge in Rare Disease Studies

Site activation is one of the most time-consuming phases in clinical trial execution—more so in rare disease research where trial urgency is high, and eligible patients are few. In these programs, delays in site activation directly affect enrollment speed, study timelines, and overall program viability.

Unlike traditional studies, rare disease trials often face added complexity due to the involvement of global centers of excellence, specialized diagnostics, and bespoke treatment regimens. A 2023 global survey showed median site activation time in rare disease trials is over 150 days, compared to 110 days for standard trials.

For sponsors and CROs, accelerating site activation can yield significant advantages in reaching patients faster and securing regulatory milestones such as Orphan Drug or Breakthrough Therapy designations.

Understanding the Site Activation Workflow

Site activation involves a series of overlapping activities that must be completed before a site can enroll its first patient. These include:

• Feasibility assessments: Evaluating investigator interest, experience, and patient access
• Budget and contract negotiations: Including confidentiality agreements and clinical trial agreements (CTAs)
• Regulatory and ethics submissions: National competent authority and institutional review board (IRB)/ethics committee (EC) approvals
• Site initiation visit (SIV): Conducted to train staff and review trial logistics
• Essential document collection: 1572, GCP certificates, lab certifications, etc.
• System access setup: For EDC, IVRS, central labs, and safety reporting platforms

In rare disease trials, additional requirements such as genetic testing certifications, compassionate use protocols, and named-patient procedures further slow down activation.

Common Bottlenecks in Rare Disease Site Activation

Several factors contribute to prolonged activation timelines in orphan drug studies:

• Specialist site dependency: Limited number of qualified centers globally
• IRB/EC approval delays: Especially where genetic testing or pediatric protocols are involved
• Contract negotiation complexity: Academic centers often have rigid contracting processes
• Vendor readiness: Delays in central lab kit supply or validated electronic platforms
• Limited site resources: Investigators may be overburdened or lack study coordinators

For example, in a global SMA trial, a premier neuromuscular center in Europe delayed activation by 10 weeks due to backlog in EC approvals and lack of translator support for patient-facing documents.

Regulatory Pathways and Their Impact on Activation

Each country presents a different regulatory landscape for rare disease trials. Sponsors must navigate multiple layers of authority:

• US: FDA IND submissions and IRB review (can be parallel)
• EU: Clinical Trial Regulation (CTR) with a centralized submission process (CTIS)
• Japan: PMDA approval and local EC requirements
• India: DCGI and ethics clearance, with emphasis on compensation clauses

Leveraging pre-submission meetings and utilizing established templates for patient information leaflets and consent forms can shave weeks off regulatory timelines.

To explore rare disease trials currently in start-up across regions, see Japan’s Clinical Trials Registry.

Strategies to Accelerate Site Activation Timelines

Practical steps sponsors and CROs can implement include:

• Centralized feasibility models: Reduce back-and-forth with standardized questionnaires
• Parallel processing: Initiate contract negotiation and regulatory submissions simultaneously
• Pre-qualified site networks: Use vetted centers with track records in rare disease
• Pre-SIV document collection: Gather documents like medical licenses and lab certifications in advance
• Contract language libraries: Create pre-approved clauses to reduce legal review cycles

Engaging sites early and setting clear expectations regarding timelines and responsibilities can also improve alignment.

Leveraging CRO Partnerships and Technology

Clinical Research Organizations (CROs) with dedicated rare disease experience can streamline activation through:

• Global regulatory knowledge: Understanding of expedited review channels and ethics nuances
• Digital activation dashboards: Real-time visibility into start-up status
• e-Feasibility tools: For rapid site screening and documentation
• Remote SIVs: Faster initiation and reduced travel logistics

Technology-enabled site selection and activation platforms are increasingly critical for complex trials with low patient density.

Key Metrics to Monitor Site Activation Efficiency

Operational teams should track metrics such as:

• Time from site selection to SIV (target: ≤60 days)
• Time from SIV to first patient in (FPI)
• Document completeness at SIV (target: ≥95%)
• Number of contract cycles before finalization
• Reasons for delay per site and country

Establishing activation KPIs enables early detection of issues and facilitates continuous improvement.

Conclusion: Building Agility into Rare Disease Site Activation

Accelerating site activation is not a one-size-fits-all task—especially in rare disease trials. However, by applying structured, regionally adapted, and technology-driven approaches, sponsors can significantly shorten activation timelines while preserving quality and compliance.

Ultimately, faster site activation means earlier patient access to investigational therapies, which is particularly critical in life-limiting and underserved conditions.